Comparative Pharmacology
Head-to-head clinical analysis: SURFAXIN versus SURVANTA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SURFAXIN versus SURVANTA.
SURFAXIN vs SURVANTA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
SURFAXIN (lucinactant) is a synthetic pulmonary surfactant that reduces surface tension at the air-liquid interface in the alveoli, preventing alveolar collapse and improving lung compliance and gas exchange. It contains phospholipids and surfactant protein B analog.
Survanta is a natural bovine lung extract containing phospholipids, neutral lipids, and surfactant-associated proteins. It reduces surface tension in the alveoli, preventing alveolar collapse at end-expiration and improving lung compliance.
Intratracheal administration: 105 mg phospholipids per kg birth weight (1.5 mL/kg of 35 mg/mL suspension) every 12 hours up to 3 doses total.
100 mg phospholipids/kg (4 mL/kg) intratracheally, administered as 4 divided aliquots, repeated every 6 hours up to 4 doses as needed.
None Documented
None Documented
Not applicable; Surfaxin is not systemically absorbed. Local pulmonary half-life is not clinically relevant.
terminal elimination half-life of approximately 67 hours (range 37-85 hours) due to slow clearance from lungs; clinically, effects persist for days after single dose
Surfaxin (lucinactant) is administered intratracheally and acts locally in the lungs. There is no significant systemic absorption; therefore, excretion pathways are not applicable. The phospholipid components are metabolized and recycled in the lung.
primarily pulmonary uptake and catabolism; minimal renal or biliary excretion; elimination via alveolar macrophages and recycling in surfactant
Category C
Category C
Pulmonary Surfactant
Pulmonary Surfactant